From Medscape Oncology

American Society of Hematology (ASH) 2017 Annual Meeting

December 09 - 12, 2017; Atlanta, Georgia

December 09 - 12, 2017 Atlanta, Georgia

ASH Oral Agents for Cancer-Related VTE: 'New Standard of Care' The oral agent rivaroxaban was as effective as subcutaneous dalteparin in controlling VTE in patients with cancer but was associated with a higher rate of bleeding.
Medscape Medical News, December 18, 2017
ASH CAR T Cells in Advanced R/R Lymphoma: Keeping Patients Alive New longer-term data on CAR T cells in patients with refractory and relapsed (R/R) lymphoma show that responses are durable, with about half of patients alive after a year or more.
Medscape Medical News, December 11, 2017
ASH Mastocytosis Becomes a 'Disease You Don't Want to Miss' A novel drug designed specifically to target a mutation found in 90% of cases shows marked activity, and has already sparked an increase in interest in this disease.
Medscape Medical News, December 10, 2017

Top News From ASH 2017: Slideshow Hot topics include moving to newer oral anticoagulants for cancer patients with VTE, plus practice-changing results in chronic lymphocytic leukemia, multiple myeloma, and Hodgkin's lymphoma.

Bendamustine Toxicity in FL Raises Eyebrows -- and Questions Results from the GALLIUM study in follicular lymphoma (FL) showed that fatal toxicity was higher with bendamustine compared with other regimens. What does this mean for clinical practice?
Medscape Medical News, Dec 19, 2016
For Trauma Use — Dried Blood Powder, Just Add Water It may be a decade before it becomes a reality, but artificial blood cells could be life-saving on the battlefield and for trauma victims.
Medscape Medical News, Dec 3, 2016
Largest Trial of Transplants in Myeloma: No Need for Extras A pivotal phase 3 trial showed no extra benefit from a double rather than a single transplant, or from adding consolidation therapy.
Medscape Medical News, Dec 15, 2016

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Medscape Oncology Insights

Previous Coverage